Faculty

Dr. Timothy Yap is a Medical Oncologist and Physician-Scientist, and the Ransom Horne, Jr. Endowed Professor for Cancer Research at the University of Texas MD Anderson Cancer Center. He serves as Vice President and Head of Clinical Development, Therapeutics Discovery Division, a drug discovery biopharmaceutical division where drug discovery and clinical translation are seamlessly integrated. Dr. Yap is a Professor in the Department of Investigational Cancer Therapeutics (Phase I Program) where he leads the design and conduct of phase 1/2 clinical trials and translational studies.

Dr. Yap’s main research focuses on the first-in-human and combinatorial development of molecularly targeted agents and immunotherapies, and their acceleration through clinical studies using novel predictive and pharmacodynamic biomarkers. His main interests include the targeting of the DNA damage response (DDR) with novel therapeutics, such as Werner Helicase, ATR, PARP1, WEE1, POLQ, USP1, PKMYT1, PARG, CHK1, ATM and DNA-PK inhibitors, next generation CDK2, CDK4 and CDK7-selective inhibitors, YAP/TEAD inhibitors, SMARCA2 degraders, as well as the development of novel immunotherapeutics.